CD274 and neoplasm: To explore the mechanisms for the refractory phenotypes of tumors to ICB therapy, we developed an ICB-refractory CT26 P3 tumor model generated from an ICB-susceptible parental cell line, CT26 P0, through three rounds of in vivo selection by anti-PD-L1 therapy (Fig. 2a).